News | January 18, 2023
Glenmark to divest select dermatology brands for Rs. 340.48 Cr
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
The implementing agency of PMBJP has invited online applications for opening of new Jan Aushadhi Kendras in 651 districts of different States/UTs
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
A study by Agharkar Research Institute (ARI), Pune, has discovered that a protein secreted from intervertebral disc cells induces disc regeneration in aged degenerated discs
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Subscribe To Our Newsletter & Stay Updated
